|
Résultats pour
brevets
1.
|
RECOMBINANT DNA ELEMENTS FOR THE EXPRESSION OF RECOMBINANT PROTEINS IN A HOST CELL
Numéro d'application |
RU2012000455 |
Numéro de publication |
2012/169939 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2012-06-13 |
Date de publication |
2012-12-13 |
Propriétaire |
ALTERNATIVE GENE EXPRESSION, S.L. (ALGENEX) (Espagne)
|
Inventeur(s) |
- Gomez Sebastian, Silvia
- Lopez Vidal, Javier
- Martinez Escribano, Jose Angel
|
Abrégé
Reagents and methods are provided that allow for art Improved expression of a recombinant protein. More specifically, the Introduction of recombinant DNA elements into a host coll allows for the increased expression of a recombinant protein, an improvement of the correct folding of said protein and an increase in cell viability and proliferation of the host cell. These recombinant DNA elements can be introduced into host cells, for example, via a recombinant baculovirus, which has incorporated said elements. The recombinant DNA elements include nucleic acids encoding transcriptional regulators, such as IE-0 and IE-1, transcriptional enhancer elements, such as the homologous region (hr) and promoters.
Classes IPC ?
- C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
- C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
- C12N 15/33 - Gènes codant pour des protéines virales
- C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
- C12P 21/00 - Préparation de peptides ou de protéines
- C07K 14/01 - Virus à ADN
|
2.
|
RECOMBINANT DNA ELEMENTS FOR THE EXPRESSION OF RECOMBINANT PROTEINS IN INSECTS
Numéro d'application |
RU2012000456 |
Numéro de publication |
2012/169940 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2012-06-13 |
Date de publication |
2012-12-13 |
Propriétaire |
- ALTERNATIVE GENE EXPRESSION, S.L. (ALGENEX) (Espagne)
- OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "LAISENTEK" (Russie)
|
Inventeur(s) |
- Gómez Sebastián, Silvia
- López Vidal, Javier
- Martínez Escribano, José Angel
|
Abrégé
Reagents and methods are provided that allow for an improved expression of a recombinant protein in an insect More specifically, the introduction of recombinant DNA elements into an insect larva allows for the increased expression of a recombinant protein, an improvement of the correct folding of said protein and an increase in the survival rate after infection of the insect These recombinant DNA elements can be introduced, for example, into insect larvae via a recombinant baculovirus, which has incorporated said elements. The recombinant DNA elements include nucleic acids encoding transcriptional regulators, such as IE-0 and lE-1, transcriptional enhancer elements, such as the homologous region (hr) and promoters.
Classes IPC ?
- A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
- C12N 15/33 - Gènes codant pour des protéines virales
- C12P 21/00 - Préparation de peptides ou de protéines
- C07K 14/01 - Virus à ADN
|
3.
|
Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8
Numéro d'application |
12739415 |
Numéro de brevet |
08592552 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2008-10-20 |
Date de la première publication |
2012-11-15 |
Date d'octroi |
2013-11-26 |
Propriétaire |
- Alternative Gene Expression, S.L. (Algenex) (Espagne)
- Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (Espagne)
|
Inventeur(s) |
- Alonso Martí, Covadonga
- Hernaez De La Plaza, Bruno
- Martinez Escribano, José Angel
|
Abrégé
New antiviral peptides interfering the binding of the virus to DLC8 are provided. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.
Classes IPC ?
- C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
- A61K 38/00 - Préparations médicinales contenant des peptides
|
4.
|
HUMAN PAPILLOMAVIRUS LIKE STRUCTURES PRODUCED IN A NON-FERMENTATIVE SYSTEM BASED ON INSECT LARVA
Numéro d'application |
EP2009066998 |
Numéro de publication |
2011/069562 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2009-12-11 |
Date de publication |
2011-06-16 |
Propriétaire |
ALTERNATIVE GENE EXPRESSION, S.L. (ALGENEX) (Espagne)
|
Inventeur(s) |
- Gómez-Sebastián, Silvia
- Fernández-San Millán, Alicia
- Nuñez, Maria Carmen
- Veramendi, Jon
- Martínez Escribano, José Ángel
|
Abrégé
Human papillomavirus like structures produced in a non-fermentative system based on insect larva. Sexually transmitted human papillomavirus (HPV) infections cause most cervical cancers. The inability to propagate HPV in vitro has led to the development of alternative approaches to antigen production for vaccine development. In the present invention we describe a low-cost efficient production of HPV pentamers or virus-like particles (VLPs) inanon-fermentative system based on baculovirus and Tήchoplusia ni (T. ni) insects as living biofactories. Th e L1 protein from HPV 16 was expressed by a recombinant baculovirus in larva at levels that reached 18 to 21 mg per g of fresh insect biomass. It represents about 2.5 times the L1 production yields obtained per g of insect cells using the same recombinant baculovirus. Under electron microscopy, purified VLPs produced in larvae were indistinguishable from those produced in Sf-21 insect cell cultures, presenting identical shape and size. Immunization of mice with the insect-derived VLPs induced a potent immune response similar to that obtained with insect cells-derived VLPs.
Classes IPC ?
- A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
- A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
- C12N 15/866 - Vecteurs baculoviraux
|
5.
|
INSECT-DERIVED PROMOTERS FOR FOREIGN PROTEINS EXPRESSION IN INSECT CELLS
Numéro d'application |
EP2008061580 |
Numéro de publication |
2010/025764 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2008-09-02 |
Date de publication |
2010-03-11 |
Propriétaire |
ALTERNATIVE GENE EXPRESSION S.L. (ALGENEX) (Espagne)
|
Inventeur(s) |
- Gómez Sebastián, Silvia
- López Vidal, Javier
- Sánchez Ramos, Ismael
- Alonso Martí, Covadonga
- Martínez Escribano, José, Angel
|
Abrégé
Insect-derived promoters for foreign proteins expression in insect cells. Regulatory polynucleotide sequences which drive the expression of major insect proteins (hexamerins) at specific evolution stages of larva have been isolated from insects (Trichoplusia ni) in the present invention. Said regulatory polynucleotide sequences promote stronger foreign gene expression in the baculovirus system than the conventional polyhedrin promoter. Additionally, the combination of the new larva-derived promoters of the invention with the pL promoter increased baculovirus expression levels up to 61%-375% (depending on the time of infection) with respect to conventional baculo viruses used in the biotechnology industry. Promoter pB2 also drives gene expression at earlier times than polyhedrin promoter, being this feature a great advantage for correct protein folding and posttranslational modification.
Classes IPC ?
- C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
- C12N 15/866 - Vecteurs baculoviraux
- A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
|
6.
|
MONOMERIC VHH DOMAIN DERIVED FROM ANTI-VP6 CAMELID ANTIBODIES, DIMERIC DOMAIN, IMMUNISATION METHOD, ROTAVIRUS DETECTION METHOD, COMPOSITION, PREVENTION AND TREATMENT METHODS FOR ROTAVIRUS INFECTIONS
Numéro d'application |
EP2008059745 |
Numéro de publication |
2009/016100 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2008-07-24 |
Date de publication |
2009-02-05 |
Propriétaire |
- ALTERNATIVE GENE EXPRESSION, S.L. (ALGENEX) (Espagne)
- INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA (INTA) (Argentine)
|
Inventeur(s) |
- Surrey, Thomas
- Olichon, Aurelien
- Garaicoeachea, Lorena Laura
- Marcoppido, Gisela Ariana
- Parreño, Gladys Viviana
- Gómez Sebastián, Silvia
- Martínez Escribano, José Angel
- Wigdorovitz, Andrés
|
Abrégé
Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus.
Classes IPC ?
- C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
- A61P 1/06 - Antispasmodiques, p. ex. médicaments pour le traitement des coliques, des dyskinésies œsophagiennes
- A61P 31/14 - Antiviraux pour le traitement des virus ARN
|
|